新股配售 | 凱萊英一手中籤率100%,國配認購4.5倍,A股溢價51.7%
uSMART盈立智投12月9日消息,凱萊英(6821)今日公佈中籤結果,並將於16:15-18:30進行暗盤交易。
配售簡況
- 發售價:388港元,爲招股區間350-410港元的中上限,A股凱萊英現價約479元(7港元),較港股定價溢價51.7%,泰格醫藥A/H溢價42%,藥明康德A/H溢價4%,康龍化成A/H溢價46%
- 上市市值:74億港元
- 一手市值:38800港元,每手100股
- 有效申購人數:4746名,甲組4702名,乙組44名
- 中籤人數:4746名,3499名中1手
- 中籤概況:一手中籤率100%,甲尾中23手(24萬港元),乙頭中95手(368.6萬港元),頂頭槌0張
- 公開認購倍數:61倍,甲組1.63倍,乙組1.6倍
- 國際發售:認購5倍,102名承配人
- 回撥情況:公開佔比10%,國配佔比90%
- 超額配股權:國配超額分配23萬股,佔發售股份的15%,穩價期於1月2日結束,穩價人高盛
注:以上佔比均假設超額配股權未獲行使
分配基準


關聯客戶

A股股東承配人

股權集中度

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.